CDKN2A and glioblastoma: These include CDKN2A/B homozygous deletion mutation, TERT promoter mutation, EGFR gene amplification, and combined gain of entire chromosome 7 and loss of entire chromosome (+7/−10) as qualifying for the diagnosis of GBM, IDH-wildtype (Table 2) [4].